Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Erdelyi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Archives of Disease in Childhood. Education and Practice Edition|May 14, 2011
Urine catecholamines in paediatricsDaniel J Erdelyi, Martin Elliott, Bob Phillips
Pathology Oncology Research : POR|February 1, 2017
Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic LeukemiaTamas Farkas, Judit Müller, Daniel J Erdelyi, et al.
Anti-Cancer Drugs|November 29, 2012
Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemiaKatalin Csordas, Marta Hegyi, Oliver T Eipel, et al.
Pathology Oncology Research : POR|June 26, 2008
Late immune recovery in children treated for malignant diseasesGabor T Kovacs, Olga Barany, Barbara Schlick, et al.
British Journal of Haematology|April 10, 2014
Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemiaKatalin Csordas, Orsolya Lautner-Csorba, Agnes F Semsei, et al.
Pediatric Blood & Cancer|January 6, 2015
Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemiaKrisztina Mita Gabor, Geza Schermann, Orsolya Lautner-Csorba, et al.
Oncotarget|August 28, 2016
Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcomaMarta Hegyi, Adam Arany, Agnes F Semsei, et al.
Cell Biology International|September 21, 2011
ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemiaAgnes F Semsei, Daniel J Erdelyi, Ildiko Ungvari, et al.
British Journal of Haematology|June 26, 2024
Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group StudyStavroula Anastasopoulou, Gemma Swann, Liv Andres-Jensen, et al.
Nature Genetics|May 11, 2010
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia riskAmy L Sherborne, Fay J Hosking, Rashmi B Prasad, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Archives of Disease in Childhood. Education and Practice Edition|May 14, 2011
Urine catecholamines in paediatricsDaniel J Erdelyi, Martin Elliott, Bob Phillips
Pathology Oncology Research : POR|February 1, 2017
Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic LeukemiaTamas Farkas, Judit Müller, Daniel J Erdelyi, et al.
Anti-Cancer Drugs|November 29, 2012
Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemiaKatalin Csordas, Marta Hegyi, Oliver T Eipel, et al.
Pathology Oncology Research : POR|June 26, 2008
Late immune recovery in children treated for malignant diseasesGabor T Kovacs, Olga Barany, Barbara Schlick, et al.
British Journal of Haematology|April 10, 2014
Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemiaKatalin Csordas, Orsolya Lautner-Csorba, Agnes F Semsei, et al.
Pediatric Blood & Cancer|January 6, 2015
Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemiaKrisztina Mita Gabor, Geza Schermann, Orsolya Lautner-Csorba, et al.
Oncotarget|August 28, 2016
Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcomaMarta Hegyi, Adam Arany, Agnes F Semsei, et al.
Cell Biology International|September 21, 2011
ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemiaAgnes F Semsei, Daniel J Erdelyi, Ildiko Ungvari, et al.
British Journal of Haematology|June 26, 2024
Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group StudyStavroula Anastasopoulou, Gemma Swann, Liv Andres-Jensen, et al.
Nature Genetics|May 11, 2010
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia riskAmy L Sherborne, Fay J Hosking, Rashmi B Prasad, et al.
Pageof 1